Want to see CYTK full AI Analyst Report?

Cytokinetics (CYTK) Stock Forecast & Price Target

1,307 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CYTK Analyst Ratings

Strong Buy

15 Buy

1 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Cytokinetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CYTK Stock 12 Month Forecast

Average Price Target

$110.93

▲(37.40% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $110.93 with a high forecast of $146.00 and a low forecast of $85.00. The average price target represents a 37.40% change from the last price of $80.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"$35","63":"$63","91":"$91","119":"$119","147":"$147"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":146,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$146.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110.93333333333332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$110.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$85.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,63,91,119,147],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.13,82.4276923076923,87.72538461538461,93.02307692307691,98.32076923076923,103.61846153846153,108.91615384615383,114.21384615384615,119.51153846153846,124.80923076923077,130.10692307692307,135.4046153846154,140.70230769230767,{"y":146,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.13,79.7302564102564,82.33051282051281,84.93076923076923,87.53102564102564,90.13128205128204,92.73153846153845,95.33179487179487,97.93205128205128,100.53230769230768,103.13256410256409,105.7328205128205,108.3330769230769,{"y":110.93333333333332,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.13,77.73538461538462,78.34076923076923,78.94615384615385,79.55153846153846,80.15692307692308,80.76230769230769,81.36769230769231,81.97307692307692,82.57846153846154,83.18384615384615,83.78923076923077,84.39461538461538,{"y":85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.84,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.43,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.61,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.35,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.68,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.26,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.13,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$146.00

Average Price Target$110.93

Lowest Price Target$85.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Srikripa Devarakonda

Truist Financial

$112

Buy

38.72%

Upside

Reiterated

08/11/26

Truist Financial Keeps Their Buy Rating on Cytokinetics (CYTK)

Yasmeen Rahimi

Piper Sandler

$107

Buy

32.52%

Upside

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX), Cytokinetics (NASDAQ: CYTK) and Scholar Rock Holding (NASDAQ: SRRK)

Leonid Timashev

RBC Capital

$117→$112

Buy

38.72%

Upside

Reiterated

08/07/26

Cytokinetics (CYTK) Gets a Buy from RBC Capital

Cory Kasimov

Evercore ISI

$100

Buy

23.85%

Upside

Reiterated

08/07/26

Cytokinetics (CYTK) Gets a Buy from Evercore ISI

Joseph Pantginis

H.C. Wainwright

$140

Buy

73.40%

Upside

Reiterated

08/07/26

Cytokinetics: Strong MYQORZO Launch and Upcoming Catalysts Support Buy Rating and Unchanged $140 Price Target

Jason Butler

Citizens JMP

$105→$110

Buy

36.24%

Upside

Reiterated

08/07/26

Cytokinetics price target raised to $110 from $105 at CitizensCytokinetics price target raised to $110 from $105 at Citizens

Serge Belanger

Needham

$102→$112

Buy

38.72%

Upside

Reiterated

08/07/26

Cytokinetics (CYTK) Receives a Buy from Needham

Paul Choi

Goldman Sachs

―

Buy

―

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Immunocore Holdings (NASDAQ: IMCR)

James Condulis

Stifel Nicolaus

$108

Buy

33.76%

Upside

Reiterated

08/07/26

Stifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)

Jason Zemansky

Bank of America Securities

$83→$85

Hold

5.28%

Upside

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Cytokinetics (NASDAQ: CYTK) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Mayank Mamtani

B. Riley Securities

$146

Buy

80.83%

Upside

Reiterated

07/31/26

B. Riley Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)

Maxwell Skor

Morgan Stanley

$103

Buy

27.57%

Upside

Assigned

07/23/26

Cytokinetics (CYTK) Receives a Buy from Morgan Stanley

Eric Joseph

Citi

$99

Buy

22.62%

Upside

Reiterated

07/16/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Ashwani Verma

UBS

$115

Buy

42.43%

Upside

Upgraded

06/29/26

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Cytokinetics (NASDAQ: CYTK)

Salim Syed

Mizuho Securities

$100→$118

Buy

46.15%

Upside

Reiterated

06/23/26

Mizuho Securities Keeps Their Buy Rating on Cytokinetics (CYTK)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Srikripa Devarakonda

Truist Financial

$112

Buy

38.72%

Upside

Reiterated

08/11/26

Truist Financial Keeps Their Buy Rating on Cytokinetics (CYTK)

Yasmeen Rahimi

Piper Sandler

$107

Buy

32.52%

Upside

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (NASDAQ: CTMX), Cytokinetics (NASDAQ: CYTK) and Scholar Rock Holding (NASDAQ: SRRK)

Leonid Timashev

RBC Capital

$117→$112

Buy

38.72%

Upside

Reiterated

08/07/26

Cytokinetics (CYTK) Gets a Buy from RBC Capital

Cory Kasimov

Evercore ISI

$100

Buy

23.85%

Upside

Reiterated

08/07/26

Cytokinetics (CYTK) Gets a Buy from Evercore ISI

Joseph Pantginis

H.C. Wainwright

$140

Buy

73.40%

Upside

Reiterated

08/07/26

Cytokinetics: Strong MYQORZO Launch and Upcoming Catalysts Support Buy Rating and Unchanged $140 Price Target

Jason Butler

Citizens JMP

$105→$110

Buy

36.24%

Upside

Reiterated

08/07/26

Cytokinetics price target raised to $110 from $105 at CitizensCytokinetics price target raised to $110 from $105 at Citizens

Serge Belanger

Needham

$102→$112

Buy

38.72%

Upside

Reiterated

08/07/26

Cytokinetics (CYTK) Receives a Buy from Needham

Paul Choi

Goldman Sachs

―

Buy

―

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK) and Immunocore Holdings (NASDAQ: IMCR)

James Condulis

Stifel Nicolaus

$108

Buy

33.76%

Upside

Reiterated

08/07/26

Stifel Nicolaus Sticks to Its Buy Rating for Cytokinetics (CYTK)

Jason Zemansky

Bank of America Securities

$83→$85

Hold

5.28%

Upside

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Cytokinetics (NASDAQ: CYTK) and BioMarin Pharmaceutical (NASDAQ: BMRN)

Mayank Mamtani

B. Riley Securities

$146

Buy

80.83%

Upside

Reiterated

07/31/26

B. Riley Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)

Maxwell Skor

Morgan Stanley

$103

Buy

27.57%

Upside

Assigned

07/23/26

Cytokinetics (CYTK) Receives a Buy from Morgan Stanley

Eric Joseph

Citi

$99

Buy

22.62%

Upside

Reiterated

07/16/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Ashwani Verma

UBS

$115

Buy

42.43%

Upside

Upgraded

06/29/26

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Cytokinetics (NASDAQ: CYTK)

Salim Syed

Mizuho Securities

$100→$118

Buy

46.15%

Upside

Reiterated

06/23/26

Mizuho Securities Keeps Their Buy Rating on Cytokinetics (CYTK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

3 Months

Tessa RomeroJ.P. Morgan

Success Rate

16/24 ratings generated profit

Average Return

+25.74%

Copying Tessa Romero's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +25.74% per trade.

1 Year

Joseph PantginisH.C. Wainwright

Success Rate

15/18 ratings generated profit

Average Return

+45.02%

Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +45.02% per trade.

2 Years

Yasmeen RahimiPiper Sandler

Success Rate

16/18 ratings generated profit

Average Return

+47.44%

Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +47.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CYTK Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CYTK has received 23 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. CYTK average Analyst price target in the past 3 months is 110.93.

Each month's total comprises the sum of three months' worth of ratings.

CYTK Financial Forecast

CYTK Earnings Forecast

Next quarter’s earnings estimate for CYTK is -$1.47 with a range of -$1.65 to -$1.10. The previous quarter’s EPS was -$1.50. CYTK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 53.85% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Sales Forecast

Next quarter’s sales forecast for CYTK is $37.81M with a range of $26.00M to $51.38M. The previous quarter’s sales results were $28.62M. CYTK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 84.62% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Stock Forecast FAQ

What is CYTK’s average 12-month price target, according to analysts?

Based on analyst ratings, Cytokinetics’s 12-month average price target is 110.93.

What is CYTK’s upside potential, based on the analysts’ average price target?

Cytokinetics has 37.40% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CYTK a Buy, Sell or Hold?

Cytokinetics has a consensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.

What is Cytokinetics’s price target?

The average price target for Cytokinetics is 110.93. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $146.00 ,the lowest forecast is $85.00. The average price target represents 37.40% Increase from the current price of $80.74.

What do analysts say about Cytokinetics?

Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of CYTK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cytokinetics (CYTK) Stock Forecast & Price Target

CYTK Analyst Ratings

CYTK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cytokinetics

CYTK Analyst Recommendation Trends

CYTK Financial Forecast

CYTK Earnings Forecast

CYTK Sales Forecast

CYTK Stock Forecast FAQ

Detailed List of Analyst Forecasts